References in periodicals archive ?
Key Takeaways of the Low Molecular Weight Heparin Market:*The global low molecular weight heparin market is expected to witness a CAGR of 6.7% during the forecast period (2018 - 2026), owing to increasing research and development activities in LMWH, globally *Among drugs, the enoxaparin segment accounted for major market share in 2017.
In our cases, we started the LMWH treatment and continued with oral anticoagulants.
LMWH was the most commonly used pharmacological prophylaxis (n=87, 87%), with new oral anticoagulants (NOACs) (non-vitamin K antagonists) in 8 (8%).
In our patient, the anticoagulant treatment was initiated with LMWH, and continued with VKA (acenocoumarol).
These results demonstrate that the addition of LMWH in the SC of moderately severe and severe AP is a safe and effective method in the prevention of PN and local and systemic complications.
In the ischemic type of stroke, intermittent pneumatic compression device and LMWH were effective in preventing DVT.
Pharmacological prophylaxis includes subcutaneously administered UFH, LMWH, warfarin, and fondaparinux.
Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies--systematic review and meta-analysis.
The purpose of this study was to compare pain and bruising associated with subcutaneous injection of the LMWH enoxaparin at two sites: abdomen and arm.
As a result, HU and antithrombosis (LMWH, warfarin, and then aspirin) were carried out.
* It is recommended to start LMWH 6-12 hours after surgery, provided there is no active bleeding.
Importantly, randomized trials comparing LMWH to UFH for the treatment of thrombosis have also indicated that heparins may improve outcomes of patients with cancer, particularly in those with early stage disease cancer including HCC and in patients with small cell lung [28, 29].
Acronyms browser ?
Full browser ?